latest analyst news is that complication rate of cataracts 87% and increases in intraocular pressure which if uncontrolled could lead to blindness are casting doubt about FDA approval. I guess thats the risk in biotech investing
PVA Price at posting:
$5.88 Sentiment: Sell Disclosure: Held